BTI, Home of the HighFive™ Cell Lines

A blue microscope icon

CHOOSE HighFive

Find out why the HighFive cell lines are a popular tool for protein production

An open book

IN THE LITERATURE

Read some of the most relevant articles

Blue circles representing cells

AVAILABLE CELL LINES

Use the original HighFive cell line or virus-free sub-clones

An icon of a cabbage looper

HighFive HISTORY

The HighFive cell line was originally developed at BTI

Choose  HighFive

Under Construction

Available Cell Lines

All listed cell lines are the property of BTI.
All listed cell lines are available for Research Use Only under MTA and for commercial licensing.
Please contact the BTI Technology Transfer Office.

Cell Line Description Available from
HighFive Original BTI-TN-5B1-4 cell line Thermo Fisher
HighFive-VF HighFive sub-clone free of alphanodavirus BTI
Tnao38 HighFive sub-clone free of alphanodavirus BTI
Tnms42 HighFive sub-clone free of alphanodavirus BTI
Tnms42-sf Tnms42 sub-clone adapted to serum-free medium Acib*/BOKU University** (contact BTI)

* Austrian Centre of Industrial Biotechnology
** University of Natural Resources and Life Sciences, Vienna

HighFive-Logos

In the Literature

Under Construction

HighFive History

BTI, home of the HighFive cell lines.

Dr. Robert Granados was looking for ways to defend crops from the Cabbage Looper. During his research he made an unexpected discovery. The HighFive cell line and newer sub-clones free of nodavirus are a popular tool for recombinant protein production.

BTI is the exclusive owner of the proprietary HighFive cell line and related sub-clones. Contact us to inquire about cell lines available for testing and request commercial-use licenses

Most people who encounter the cabbage looper, a green caterpillar pest that dines on vegetable crops, would call it a pest and leave it at that. But thanks in part to research at BTI, these humble garden nuisances have transcended their bad reputation by helping lead to the creation of a life-saving vaccine.

This unlikely connection came about thanks to insect virologist and BTI (now) Emeritus scientist Bob Granados, who was working at the time on developing genetically-engineered baculoviruses–a specific family of rod-shaped viruses that typically infect invertebrates–for biocontrol of insect pests in crops. In order to grow the viruses, Granados needed a reliable host. By 1994, he settled on none other than the cabbage looper–using cells from the insect as virus incubators. These cells were so effective at producing the key proteins necessary for biocontrol research, the line was patented, and became a standard tool in the Granados and other research labs–nicknamed the “High Five” cell line.

Prior to this work, medical researchers began to investigate the feasibility of developing vaccines for Human Papilloma Virus (HPV), the most common sexually-transmitted disease that infects 14 million people every year. With persistent infection, the virus can lead to cervical and other cancers.

Scientists looked into using baculoviruses as a safe method for engineering HPV-neutralizing antigens which could be given as a vaccine. And, like Granados, they needed a stable host cell to grow their engineered baculoviruses in. “A lot of labs were looking for a good insect line to do this work,” said Paul Debbie, Director of Research and Director of New Business Development. “They needed it to be stable, and able to produce a lot of protein–so Bob did some work to see if the High Five cell line could work for this, and it was.”

Through research collaborations with scientists at other universities and institutes, and through partnering with drug development companies MedImmune and GlaxoSmithkline, Granados’ High Five cabbage looper cell line became the vehicle for producing the HPV vaccine known as Cervarix, one of the only two HPV vaccines available today.

Debbie says that this achievement would never have been possible without the diligent scientific research done by Granados and his counterparts. “There were all these basic science projects converging to one very useful therapeutic that saves lives,” said Debbie. “With basic research, one doesn’t necessarily know what the final outcome is going to be–it takes this very circuitous route, and it can end up having a big impact.”

Contact

Headshot of Paul Debbie

Paul Debbie

Director of Research, Director of New Business Development

ppd2@cornell.edu

Headshot of Julien Fey

Julien Fey

Director of Technology Transfer

jpf23@cornell.eduu

Headshot of Kelli Monce

Kelli Monce

Technology Transfer Specialist

ksm84@cornell.edu

 

Contact:

Boyce Thompson Institute
533 Tower Rd.
Ithaca, NY 14853
607.254.1234
contact@btiscience.org